Lurbinectedin Yields Responses in Various ES-SCLC Subgroups
Lurbinectedin achieved an ORR of 27% in all patients with extensive-stage small cell lung cancer in the phase 4 Jazz EMERGE 402 study.
Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting
Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.
WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care
Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.
Elevating Community Oncology Care: Insights From World GU 2025
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.
How Promising Are Immunotherapy Combos in Indolent Lymphoma?
Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.
Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population
Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.
